|
Protein Kinase C is an important molecule for signal transduction. An investigational compound would need to selectively target it without it affecting the numerous other cellular processes. That's likely why this is limited to solid, superficial tumors such as the one the woman with melanoma had. I wonder if it is too broad for liquid tumors (leukemias), and that's not to speak of the issues with scaling up and monitoring side effects in a patient population.
It's an interesting theory, but I'd still put much more of my anticancer money on monoclonal antibodies.
__________________
"When the Know-Nothings get control, it will read 'all men are created equal, except negroes, and foreigners, and Catholics.' When it comes to this I should prefer emigrating to some country where they make no pretense of loving liberty – to Russia, for instance, where despotism can be taken pure, and without the base alloy of hypocrisy.”--Abraham Lincoln
|